证券代码：603882 证券简称：金域医学 公告编号：2025-048 重要内容提示： 问题征集方式：投资者可于 2025 年 11 月 19 日中午 12:00 前访问网址 h ttps://eseb.cn/1t8vQO28EWQ 进行会前提问，或将相关问题通过电子邮件的 形式发送至公司证券事务部邮箱：sid@kingmed.com.cn。本公司将在业绩说 明会上对投资者普遍关注的问题进行统一回答。 广州金域医学检验集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司及 2025 年第三季度的经营成果、财务状况，公司计划于 2025 年 11 月 20 日 15:00-16:00 举行 2025 年第三季度业绩说明会（以下简称"业绩说明会"），就 投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络文字互动方式召开，公司将针对 2025 年第三季度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 1 广州金域医学检验集团股份有限公司 关 ...

Group 1 - The controlling shareholder and actual controller, Mr. Liang Yaoming, directly holds 74,191,907 shares of the company, accounting for 16.02% of the total share capital. The recent release of 6,500,000 pledged shares represents 8.76% of Mr. Liang's directly held shares and 1.40% of the total share capital [2][3] - After the release of the pledged shares, Mr. Liang and his concerted actors have a total of 31,580,000 pledged shares, which accounts for 19.14% of their total holdings and 6.82% of the company's total share capital [2][4] - Mr. Liang has no current plans to pledge the released shares again. Any changes will be communicated in accordance with relevant regulations [3][4] Group 2 - The company will closely monitor the progress of the relevant pledge matters and will disclose related information in a timely manner as per regulations [5][6]

Core Points - The company, Kingmed Diagnostics, announced the release of a portion of shares pledged by its controlling shareholder, Liang Yaoming [2] - A total of 6,500,000 shares were released from pledge, which represents 8.76% of the shares held by the shareholder and 1.40% of the company's total share capital [2]

证券代码：603882 证券简称：金域医学 公告编号：2025-047 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 剩余被质押股份数量占其所持股份比例 | 31.00% | | --- | --- | | 剩余被质押股份数量占公司总股本比例 | 4.96% | 梁耀铭先生本次解除质押的股份尚无用于后续质押的计划。如有变动，梁耀 铭先生将根据后续质押情况及时履行告知义务，公司将根据后续质押情况和相关 法律法规要求及时履行信息披露义务。 二、股东累计质押股份情况 截至本公告披露日，公司控股股东、实际控制人梁耀铭先生及其一致行动人 严婷女士、曾湛文先生以及梁耀铭先生控制的广州市圣域钫投资咨询合伙企业 （有限合伙）（以下简称"圣域钫"）、广州市鑫镘域投资咨询合伙企业（有限合 伙）（以下简称"鑫镘域"）、广州市圣铂域投资咨询合伙企业（有限合伙）（以下 简称"圣铂域"）及广州市锐致投资咨询合伙企业（有限合伙）（以下简称"锐致"） 累计质押股份情况如下 ...

Group 1 - The investment summit held by Huatai Securities emphasized a strong outlook for the revaluation of Chinese assets, particularly favoring the "old economy" sectors [2] - The China Securities Index Company announced the launch of two new indices focused on innovative drugs and medical devices, enhancing investment options in these sectors [3] - The National Healthcare Security Administration is set to release the first version of the commercial insurance innovative drug directory, aiming to support the development of innovative pharmaceuticals [3] Group 2 - Hong Kong ranked fourth globally in the 2025 World Digital Competitiveness Ranking, showing significant improvements in technology and knowledge factors [4][5] - The China Securities Regulatory Commission announced the initiation of reforms for the ChiNext board to better serve the "14th Five-Year Plan" for technological innovation [4] Group 3 - The A-share market has shown strong performance, leading to a significant increase in the number of active equity fund managers, surpassing 100 for the first time [10] - The issuance of new funds has surged, with notable demand for equity funds, as evidenced by the rapid fundraising of two "daylight funds" [8][9] Group 4 - Berkshire Hathaway reported a 34% year-on-year increase in operating profit for Q3, driven by a substantial rise in insurance underwriting profits [11] - The alternative investment management sector is increasingly recognizing the importance of the Chinese market, highlighting its vast scale and innovative potential [13] Group 5 - The MSCI announced adjustments to its important indices, with changes set to take effect on November 24, 2025 [14] - The financial regulatory authority has delegated certain administrative licensing and reporting matters to local financial regulatory branches to enhance efficiency [16] Group 6 - A notable shift in private equity fund allocations was observed, with significant adjustments in holdings among well-known private equity firms following the release of Q3 financial reports [21][22] - The market is currently experiencing a "slow bull" phase, with a focus on sectors like AI, robotics, and high-end manufacturing, despite volatility in the broader market [22]

Core Viewpoint - The announcement details the share pledge situation of the controlling shareholder, Liang Yaoming, and the associated risks for the company and its investors [1][2]. Group 1: Share Pledge Details - The controlling shareholder, Liang Yaoming, directly holds 74,191,907 shares, accounting for 16.02% of the total share capital. The pledged shares amount to 6,500,000, which is 8.76% of his directly held shares and 1.40% of the total share capital [1]. - After the pledge, the total shares pledged by Liang Yaoming and his associates, including Yan Ting and Zeng Zhanwen, as well as entities controlled by him, amounts to 38,080,000 shares, representing 23.08% of his total holdings and 8.22% of the total share capital [1][2]. - The pledged shares are not used as collateral for major asset restructuring or performance compensation [1]. Group 2: Monitoring and Disclosure - The company will closely monitor the developments related to the share pledges and will disclose relevant information in a timely manner according to regulations [2].

Core Viewpoint - Kingmed Diagnostics announced that its controlling shareholder and actual controller, Mr. Liang Yaoming, directly holds 74,191,907 shares, accounting for 16.02% of the company's total share capital. The recent pledge involves 6,500,000 shares, representing 8.76% of Mr. Liang's directly held shares and 1.40% of the company's total share capital [1]. Summary by Sections - Shareholding Structure - Mr. Liang Yaoming directly holds 74,191,907 shares, which is 16.02% of the total share capital [1]. - Pledged Shares - The recent pledge involves 6,500,000 shares, which is 8.76% of Mr. Liang's directly held shares and 1.40% of the company's total share capital [1].

证券代码：603882 证券简称：金域医学 公告编号：2025-046 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股， 占公司总股本的 16.02%。本次质押股份 6,500,000 股，占梁耀铭先生直接持有 公司股份数的 8.76%，占公司总股本的 1.40%。 本次股份质押后，公司控股股东、实际控制人梁耀铭先生及其一致行动人严 婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及锐致累计 质押 38,080,000 股，占其持有公司股份总数的 23.08%，占公司总股本的 8.22%。 一、上市公司股份质押 2、本次质押股份不涉及被用作重大资产重组业绩补偿等事项的担保或其他 保障用途的情形。 1 二、股东累计质押股份情况 截至 2025 年 11 月 6 日，公司控股股东、实际控制人梁耀铭先生及其一致行 动人严婷女士、曾湛文先生以及梁耀铭先生 ...

Group 1 - The core point of the article is that Kingmed Diagnostics (SH 603882) announced that its controlling shareholder, Liang Yaoming, has pledged 6.5 million shares, which raises concerns about the company's financial stability [1] - After the pledge, Liang Yaoming and his associates have a total of 38.08 million shares pledged, representing 23.08% of their total holdings and 8.22% of the company's total shares [1] - As of the report, Kingmed Diagnostics has a market capitalization of 13.7 billion yuan [1] Group 2 - For the year 2024, Kingmed Diagnostics' revenue composition is projected to be 92.17% from third-party medical diagnostics and 7.83% from other businesses [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][15] Core Views - The company is undergoing a transformation that is beginning to show results, with a focus on optimizing its product portfolio and enhancing the value of data elements [3][4] - The company reported a revenue of 45.38 billion yuan for the first three quarters of 2025, a year-on-year decline of 19.23%, with a net profit attributable to shareholders of -0.80 billion yuan [4][5] - The third quarter of 2025 showed signs of recovery, with revenue of 15.41 billion yuan, a year-on-year decline of 11.32%, and a net profit of 0.05 billion yuan, reflecting a 24.08% increase year-on-year [5][6] Financial Performance - The company’s revenue forecast for 2025-2027 is projected at 61.65 billion, 66.41 billion, and 71.55 billion yuan, with respective growth rates of -14%, 8%, and 8% [6][4] - The net profit attributable to shareholders is expected to be 0.10 billion, 4.41 billion, and 4.86 billion yuan for the same period, indicating a significant recovery [6][4] - The company’s current stock price corresponds to a P/E ratio of 1356, 32, and 29 for 2025-2027, reflecting its leading position in the industry and ongoing advancements in data intelligence [6][4] Operational Insights - The company has expanded its customer base and optimized its product offerings, leading to a 53.8% year-on-year increase in revenue from its public welfare product system [6][5] - The integration of AI applications has improved diagnostic efficiency, with the "Xiao Yu Yi" clinical assistant achieving over 599 million cumulative calls and 140,000 monthly active users by the third quarter of 2025 [6][5] - The company has registered six specialized disease datasets and launched 21 data products on various data trading platforms, establishing long-term data cooperation with multiple clients [6][5]